| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8245127 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 7 Pages |
Abstract
Conclusion: This first, multi-institutional FSRT boost trial for GBM was feasible and well tolerated. There is no significant survival benefit using this dose-intense RT regimen. Subset analysis revealed a trend toward improved outcome for GTR patients suggesting that patients with minimal disease burden may benefit from this form of accelerated RT.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Robert M.D., Minhee M.A., Ali M.D., Michael Ph.D., Arnab M.D., Ph.D., Christopher M.D., Luis M.D., Allan M.D., Ph.D., Huong M.D., Minesh M.D.,